AP NEWS

Bio-Thera Solutions Announces Poster Presentation at the 2018 EORTC-NCI-AACR Symposium

November 8, 2018

GUANGZHOU, China--(BUSINESS WIRE)--Nov 8, 2018--Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company will present one poster at the 2018 EORTC-NCI-AACR Symposium taking place November 13 - 16, 2018 in Dublin, Ireland.

The poster, entitled “BAT8001, a potent anti-HER2 antibody-drug conjugate with a novel stable linker for the treatment of HER2-positive gastric cancer,” will present preclinical data that highlight advantages of BAT8001 as a potential treatment for breast cancer patients. An abstract of the presentation is currently available on EORTC website.

Presentation details are as follows:

About BAT8001

BAT8001 is an investigational HER2-ADC being evaluated in multiple tumor types. HER2 is a naturally occurring receptor that is overexpressed in many types of cancer, including breast cancer and gastric cancer. BAT8001 is being developed for use as a single agent and in combination with other agents for the treatment of multiple cancers. BAT8001 is currently being evaluated in a Phase 3 clinical trial for the treatment of metastatic breast cancer patients (more information on the trial is available at http://www.chinadrugtrials.org.cn/ (CTR20180157)). The BAT8001 clinical study program will be expanded beyond metastatic breast cancer to other HER2-positive cancers, including gastric cancer, over the next 12 months.

About Antibody-Drug Conjugates

Antibody-drug Conjugates or ADCs are designed to harness the targeting ability of monoclonal antibodies (mAbs) to deliver cytotoxic agents selectively to tumor cells by linking the monoclonal antibody and cytotoxic agent through a chemical linker. An ideal ADC consists of: 1) a highly selective mAb for a tumor-associated antigen that has little or no expression on normal cells, 2) a potent cytotoxic agent designed to induce target cell death after being internalized in the tumor cell and released and 3) a chemical linker that is stable in circulation but releases the cytotoxic agent in target cells. By selectively delivering a cytotoxic agent directly inside a tumor cell, ADCs increase the safety and tolerability of the cytotoxic agent relative to giving the cytotoxic agent systemically to the patient.

About Bio-Thera Solutions

Bio-Thera Solutions Ltd, a leading global biotechnology company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. A leader in next generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials and has applied for marketing authorization for one candidate. In addition, the company has multiple promising candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases. For more information, please visit www.bio-thera.com/en/ or follow us on Twitter ( @bio_thera_sol ) and wechat (Bio-Thera).

View source version on businesswire.com:https://www.businesswire.com/news/home/20181108005159/en/

CONTACT: Bio-Thera Solutions, Ltd:

Bert E. Thomas IV +1-410-627-1734

bethomas@bio-thera.com

KEYWORD: EUROPE ASIA PACIFIC CHINA IRELAND

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE GENERAL HEALTH MANAGED CARE

SOURCE: Bio-Thera Solutions Ltd

Copyright Business Wire 2018.

PUB: 11/08/2018 08:08 AM/DISC: 11/08/2018 08:08 AM

http://www.businesswire.com/news/home/20181108005159/en

AP RADIO
Update hourly